Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5

Molecular Immunology

Volumn 45, Issue 4, 2008, Pages 1027-1034

  Gach, Johannes S ^a   Quendler, Heribert ^b   Strobach, Stefanie ^a   Katinger, Hermann ^a,b   Kunert, Renate ^a  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^b POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

Author keywords

2F5; Anti idiotypic antibodies; ELDKWA; HIV 1; Vaccine

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IDIOTYPIC ANTIBODY 3H6; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY 2F5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BAGG ALBINO MOUSE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; FEMALE; HEAVY CHAIN; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CHO CELLS; COMPLEMENTARITY DETERMINING REGIONS; CRICETINAE; CRICETULUS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; MICE; MICE, INBRED BALB C; POINT MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 35549005948     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.07.030     Document Type: Article

References (29)

1. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
2. Calarota S., Jansson M., Levi M., Broliden K., Libonatti O., Wigzell H., and Wahren B. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses 12 (1996) 705-713
3. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R., et al. Conformations of immunoglobulin hypervariable regions. Nature 342 (1989) 877-883
4. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., Dridi A., Latour M., El Habib R., Barre-Sinoussi F., Hofnung M., and Leclerc C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19 (2000) 684-693
5. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., and Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77 Pt 9 (1996) 2001-2008
6. Gach J.S., Maurer M., Hahn R., Gasser B., Mattanovich D., Katinger H., and Kunert R. High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J. Biotechnol. 128 (2007) 735-746
7. Gach, J.S., Quendler, H., Weik, R., Katinger, H., Kunert, R., in press. Partial humanisation and characterisation of an anti-idiotypic antibody against monoclonal antibody 2F5. AIDS Res. Hum. Retroviruses.
8. Gasser B., Maurer M., Gach J., Kunert R., and Mattanovich D. Engineering of Pichia pastoris for improved production of antibody fragments. Biotechnol. Bioeng. 94 (2006) 353-361
9. Geffin R.B., Scott G.B., Melenwick M., Hutto C., Lai S., Boots L.J., McKenna P.M., Kessler II J.A., and Conley A.J. Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1. AIDS Res. Hum. Retroviruses 14 (1998) 579-590
10. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2714-2723
11. Harlow E., and Lane D. Antibodies, A Laboratory Manual (1988), Cold Spring Harbor Laboratory, New York pp. 617-618
12. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Citron M.P., Danzeisen R.C., Miller M.D., Shiver J.W., and Keller P.M. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J. Biol. Chem. 277 (2002) 45811-45820
13. Kirsch R.D., Beale D., He M., Corper A.L., Krawinkel-Brenig U., and Taussig M.J. Anti-anti-idiotypic (Ab3) antibodies that bind progesterone-11α-bovine serum albumin differ in their combining site from antibodies raised directly against the antigen. Immunology 100 (2000) 152-164
14. Kunert R., Ruker F., and Katinger H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retroviruses 14 (1998) 1115-1128
15. Kunert R., Steinfellner W., Purtscher M., Assadian A., and Katinger H. Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnol. Bioeng. 67 (2000) 97-103
16. Kunert R.E., Weik R., Ferko B., Stiegler G., and Katinger H. Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS 16 (2002) 667-668
17. Liang X., Munshi S., Shendure J., Mark III G., Davies M.E., Freed D.C., Montefiori D.C., and Shiver J.W. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17 (1999) 2862-2872
18. Mascola J.R., Louder M.K., VanCott T.C., Sapan C.V., Lambert J.S., Muenz L.R., Bunow B., Birx D.L., and Robb M.L. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71 (1997) 7198-7206
19. McGaughey G.B., Citron M., Danzeisen R.C., Freidinger R.M., Garsky V.M., Hurni W.M., Joyce J.G., Liang X., Miller M., Shiver J., and Bogusky M.J. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 42 (2003) 3214-3223
20. Menendez A., Chow K.C., Pan O.C., and Scott J.K. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J. Mol. Biol. 338 (2004) 311-327
21. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., and Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68 (1994) 4031-4034
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
23. Nikula T.K., Bocchia M., Curcio M.J., Sgouros G., Ma Y., Finn R.D., and Scheinberg D.A. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol. Immunol. 32 (1995) 865-872
24. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 (1994) 1651-1658
25. Shirai H., Kidera A., and Nakamura H. H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett. 455 (1999) 188-197
26. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 (1995) 6609-6617
27. Winkler K., Kramer A., Kuttner G., Seifert M., Scholz C., Wessner H., Schneider-Mergener J., and Hohne W. Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody. J. Immunol. 165 (2000) 4505-4514
28. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
29. Zwick M.B., Parren P.W., Saphire E.O., Church S., Wang M., Scott J.K., Dawson P.E., Wilson I.A., and Burton D.R. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77 (2003) 5863-5876